Table 2: Effectiveness of weight loss treatment in children with nonalcoholic fatty liver disease.

OutcomeΔ Weight (kg)Δ Height (m)Δ BMI ( -score)Δ ALT (U/L)

( )
 Value −0.2 ± 2.9 (0.976)+0.01 ± 0.01 (0.740)−0.05 ± 0.11 (0.532)−32 ± 66 (0.016)
 Correlation 0.076 (0.611)−0.012 (0.937)
 Regression4.72 (0.107)68.8 (0.377)
( )
 Value+1.4 ± 4.8 (0.825)+0.02 ± 0.02 (0.583)−0.07 ± 0.15 (0.493)−30 ± 65 (0.134)
 Correlation0.360 (0.071)0.235 (0.247)
 Regression3.28 (0.187)101.1 (0.213)
( )
 Value +3.3 ± 4.7 (0.680)+0.03 ± 0.03 (0.425)−0.05 ± 0.15 (0.718)−37 ± 75 (0.157)
 Correlation 0.077 (0.753)0.107 (0.662)
 Regression1.08 (0.617)51.3 (0.424)
( )
 Value+7.1 ± 9.0 (0.471)+0.07 ± 0.06 (0.219)−0.12 ± 0.21 (0.453)−45 ± 69 (0.014)
 Correlation 0.371 (0.118)0.176 (0.471)
 Regression3.10 (0.073)69.0 (0.320)

: time interval 1–4 months, : time interval 5–8 months, : time interval 9–12 months, : time interval beyond one year, SD: standard deviation, ALT: alanine aminotransferase.
BMI adjusted for age and sex using the 2000 Centers for Disease Control and Prevention growth charts and lambda, mu and sigma method [17].
Values are the change in parameter presented as mean ± standard deviation with value in parentheses based on independent two-sample -test and Wilcoxon rank sum test for parametric and nonparametric continuous variables, respectively.
Association between changes in body weight and BMI -score, and changes in serum alanine aminotransferase assessed by Pearson correlation and linear regression and presented as correlation coefficients and regression coefficients with values in parentheses. Linear regression adjusted for initial serum alanine aminotransferase, and baseline values for body weight and BMI -score of the corresponding analysis.